Sign In
Buy TNDM
$18.03
-0.570 (-3.06%)
At Close: Jun 03, 2026
Why Tandem Diabetes Care Stock Took It on the Chin Tuesday
05:39pm, Tuesday, 01'st Oct 2024
Flat revenue growth might be in store for the company in a very crucial market.
t:slim X2's Compatibility With Lilly's Lyumjev Might Aid TNDM Stock
01:37pm, Tuesday, 01'st Oct 2024
By integrating ultra-rapid acting insulin such as Lyumjev, which responds faster than traditional insulin, Tandem Diabetes Care is enhancing the pump's functionality.
TNDM Stock Likely to Gain From Innovation Amid Competition
10:32am, Monday, 23'rd Sep 2024
Tandem Diabetes is driving transformative innovation to help reduce the burden of diabetes and create new possibilities for people living with the condition.
TNDM Stock Likely to Benefit From the t:slim X2-Lyumjev Offering in EU
09:35am, Monday, 23'rd Sep 2024
Tandem Diabetes' t:slim X2 insulin pump is now compatible with Lilly's Lyumjev in the European Union.
Why Tandem Diabetes Care Stock Thrashed the Market Today
06:49pm, Thursday, 19'th Sep 2024
It earned a regulatory nod in one of the largest markets in the world. Approval was granted for a system to deliver an ultra-rapid insulin product developed by Eli Lilly.
Tandem t:slim X2 Insulin Pump Now Compatible with Lyumjev Ultra-rapid Acting Insulin in European Union
09:00am, Thursday, 19'th Sep 2024
SAN DIEGO--(BUSINESS WIRE)---- $TNDM #diabetes--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2 insulin pump w
Reasons to Hold Tandem Diabetes Stock in Your Portfolio Now
09:40am, Tuesday, 03'rd Sep 2024
Innovations and a robust diabetes market outlook raise investors' optimism for TNDM.
New Launches Support Tandem Diabetes Stock Despite Macro Concerns
12:25pm, Friday, 30'th Aug 2024
The latest addition to TNDM's pump platform portfolio, Tandem Mobi, is leading the way in creating a whole new category of devices for insulin therapy.
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) today announced the planned release of version 2.8.2 of its Apple iOS t:connect mobile app in the United States on August 20, 2024
Tandem Diabetes Care Provides Update on March 2024 Nationwide Recall of t:connect Mobile App for iOS Devices
04:30pm, Monday, 12'th Aug 2024
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) today provided an update on the March 2024 recall of its Apple iOS t:connect mobile app in the United States relating to an issue
NEW YORK, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Tandem Diabetes Care, Inc. (NASD
Tandem Diabetes (TNDM) Q2 Earnings Beat, '24 View Raised
10:50am, Monday, 05'th Aug 2024
Tandem Diabetes' (TNDM) top and bottom lines outpace estimates in the second quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.
Tandem Diabetes Care, Inc. (TNDM) Q2 2024 Earnings Call Transcript
06:36am, Friday, 02'nd Aug 2024
Tandem Diabetes Care, Inc. (NASDAQ:TNDM ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Susan Morrison - Executive Vice President and Chief Administrative Officer. Jo
Tandem Diabetes Care (TNDM) Reports Q2 Earnings: What Key Metrics Have to Say
08:35pm, Thursday, 01'st Aug 2024
While the top- and bottom-line numbers for Tandem Diabetes Care (TNDM) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metri
Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Tops Revenue Estimates
07:11pm, Thursday, 01'st Aug 2024
Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.30 per share a year ago.
